There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report) and Plus Therapeutics (PSTV – Research Report) with bullish sentiments.
Actinium Pharmaceuticals (ATNM)
JonesTrading analyst Justin Walsh maintained a Buy rating on Actinium Pharmaceuticals today and set a price target of $24.00. The company’s shares closed last Wednesday at $6.54, close to its 52-week low of $5.61.
According to TipRanks.com, Walsh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $32.25 average price target, representing a 393.9% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Plus Therapeutics (PSTV)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Plus Therapeutics yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $2.39, close to its 52-week low of $1.97.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Plus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.33, representing an 1196.1% upside. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATNM:
